ArticleOncotarget2016

Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients.

Stefania Trino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.